John Glass is a professor and leader of the JCVI Synthetic Biology Group. His expertise is in molecular biology, microbial pathogenesis, RNA virology, and microbial genomics. Dr. Glass is also an adjunct faculty member of the University of Maryland at College Park Cellular and Molecular Biology Program, and member of the Global Viral Network Scientific Leadership Board.

Dr. Glass is part of the Venter Institute team that created a synthetic bacterial cell. In reaching this milestone, the Venter Institute scientists developed the fundamental techniques of the new field of synthetic genomics including genome transplantation and genome assembly. Dr. Glass was also leader of the JCVI project that rapidly made synthetic influenza virus vaccine strains in collaboration with Novartis Vaccines and Diagnostics, Inc., and Synthetic Genomics, Inc. At the JCVI he has also led the bacterial outer membrane vesicle based vaccine, genome transplantation, and Mycoplasma genitalium minimal genome projects, and projects studying other mycoplasma and ureaplasma species. Glass and his Venter Institute colleagues are now using synthetic biology and synthetic genomics approaches developed at the JCVI to create cells and organelles with redesigned genomes to make microbes that can produce biofuels, pharmaceuticals, and industrially valuable molecules.

Prior to joining the JCVI, Dr. Glass spent five years in the Infectious Diseases Research Division of the pharmaceutical company Eli Lilly. There he directed a hepatitis C virology group and a microbial genomics group (1998-2003).

Dr. Glass earned his undergraduate (Biology) and graduate degrees (Genetics) from the University of North Carolina at Chapel Hill. His PhD work was on RNA virus genetics in the laboratory of Gail Wertz. He was on the faculty and did postdoctoral fellowships in the Microbiology Department of the University of Alabama at Birmingham in polio virology with Casey Morrow and mycoplasma pathogenesis with Gail Cassell (1990-1998). On sabbatical leave in Ellison Chen’s lab at Applied Biosystems, Inc. (1995-1997) he sequenced the genome of Ureaplasma parvum and began his study of mycoplasma genomics.

Publications

Gross Chromosomal Rearrangements in Kluyveromyces marxianus Revealed by Illumina and Oxford Nanopore Sequencing.
International journal of molecular sciences. 2020-09-26; 21.19:
PMID: 32993167
Technology used to build and transfer mammalian chromosomes.
Experimental cell research. 2020-03-15; 388.2: 111851.
PMID: 31952951
Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome.
Science (New York, N.Y.). 2008-02-29; 319.5867: 1215-20.
PMID: 18218864
The Sorcerer II Global Ocean Sampling Expedition: metagenomic characterization of viruses within aquatic microbial samples.
PloS one. 2008-01-23; 3.1: e1456.
PMID: 18213365
Genome transplantation in bacteria: changing one species to another.
Science (New York, N.Y.). 2007-08-03; 317.5838: 632-8.
PMID: 17600181
Essential genes of a minimal bacterium.
Proceedings of the National Academy of Sciences of the United States of America. 2006-01-10; 103.2: 425-30.
PMID: 16407165
Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2003-05-01; 23.5: 247-57.
PMID: 12804067
The complete sequence of the mucosal pathogen Ureaplasma urealyticum.
Nature. 2000-10-12; 407.6805: 757-62.
PMID: 11048724

No More Needles!

Transforming the Treatment of Type 1 Diabetes

Show Project Video

First Minimal Synthetic Bacterial Cell

Show Project Video

No More Needles! Using Microbiome and Synthetic Biology Advances to Better Treat Type 1 Diabetes
Dr. John Glass on NSF Awards for "Understanding the Rules of Life"